RESUMEN
PURPOSE: We evaluated the attitude in using chemotherapy near the end of life in advanced pancreatic adenocarcinoma (PAC). Clinical and laboratory parameters recorded at last chemotherapy administration were analyzed, in order to identify risk factors for imminent death. METHODS: Retrospective analysis of patients who underwent at least one line of palliative chemotherapy was made. Data concerning chemotherapy (regimens, lines, and date of last administration) were collected. Clinical and laboratory factors recorded at last chemotherapy administration were: performance status, presence of ascites, hemoglobin, white blood cell (WBC), platelets, total bilirubin, albumin, LDH, C-reactive protein (C-rp), and Ca 19.9. RESULTS: We analyzed 231 patients: males/females, 53/47 %; metastatic/locally advanced disease, 80/20 %; and median age, 66 years (range 32-85). All patients died due to disease progression. Median overall survival was 6.1 months (95 % CI 5.1-7.2). At the last chemotherapy delivery, performance status was 0-1 in 37 % and 2 in 63 %. Fifty-nine percent of patients received one chemotherapy line, while 32, 8, and 1 % had second-, third-, and fourth line, respectively. The interval between last chemotherapy administration and death was <4 weeks in 24 %, ≥4-12 in 47 %, and >12 in 29 %. Median survival from last chemotherapy to death was 7.5 weeks (95 % CI 6.7-8.4). In a univariate analysis, ascites, elevated WBC, bilirubin, LDH, C-rp and Ca 19.9, and reduced albumin were found to predict shorter survival; however, none of them remained significant in a multivariate analysis. CONCLUSIONS: A significant proportion of patients with advanced PAC received chemotherapy within the last month of life. The clinical and laboratory parameters recorded at last chemotherapy delivery did not predict shorter survival.
Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Antineoplásicos , Prescripción Inadecuada , Cuidados Paliativos , Neoplasias Pancreáticas/tratamiento farmacológico , Adulto , Anciano , Anciano de 80 o más Años , Progresión de la Enfermedad , Utilización de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Pautas de la Práctica en Medicina , Estudios Retrospectivos , Análisis de Supervivencia , SuizaRESUMEN
BACKGROUND: Iodine deficiency (ID) still now represents one of the major worldwide health problems. ID is the result of insufficient dietary iodine intake. Iodine is an essential micronutrient but scarcely present in nature. The main strategy for the correction of ID is the fortification of table salt with iodide/iodine but Italy is far from reaching an iodized salt use higher 90% of population. Also because of the evidence for the risk on blood pressure, it is recommended to decrease the daily salt intake to less than 5 g/d. An opportunity to increase the iodine intake is the possibility to introduce iodine fortification in the industrial processing of foods. AIM: The aim was to evaluate the effectiveness of a diet containing iodized foods enriched during industry processing with protected iodized salt (Presal®). SUBJECTS AND METHODS: The evaluation of increasing of iodine intake was assessed by measuring the urinary iodine excretion (UIE) in 30 healthy volunteers who added to their alimentary habits a basket of iodine-enriched foodstuffs. RESULTS: Median UIE at baseline was 105 µg/l, 156 µg/l during the enriched diet and 90.5 µg/l a week after withdrawal of enriched diet. CONCLUSIONS: Stable iodized salt (Presal®) represents a good way to introduce iodine with the normal diet without increasing the normal consumption of salt for the healthy problems related to the blood pressure. The availability of stable iodized salt (Presal®) allows the preservation of iodine after cooking.
Asunto(s)
Alimentos Fortificados , Yodo/deficiencia , Adulto , Enfermedades Carenciales/epidemiología , Femenino , Humanos , Yodo/orina , Italia/epidemiología , Masculino , Persona de Mediana Edad , Proyectos Piloto , Cloruro de Sodio DietéticoRESUMEN
Dairy products offer an important source of iodine for humans, particularly infants and children. An adequate iodine content in the diet of lactating animals must guarantee a suitable milk iodine concentration. In this experiment, the effects of iodine supplementation of dairy goat diets on the iodine concentration, milk yield, and milk composition of goat milk were studied. Thirty crossbred dairy goats of the Sarda population were divided into 3 groups supplemented with 0 (control group), 0.45 (group 1), or 0.90 (group 2) mg of KI/d per goat. The dose of KI (76.5% of iodine) was dissolved in water and orally administered with a syringe every day for 10 wk. Mean milk iodine concentrations were 60.1 +/- 50.5, 78.8 +/- 55.4, and 130.2 +/- 62.0 microg/L (mean +/- SD) in the control group, group 1, and group 2, respectively. The extent of iodine enrichment in milk was approximately 31% in group 1 and 117% in group 2 compared with the control group. Milk yield was not influenced by KI supplementation and averaged 1,229, 1,227, and 1,179 g/d in groups 0, 1, and 2, respectively. Milk urea nitrogen concentration was significantly lower in the KI-supplemented groups (32 and 33 mg/dL in groups 1 and 2, respectively) than in the control group (37 mg/dL). Iodine supplementation of dairy goat diets can increase milk iodine content without adverse effects on milk production traits.
Asunto(s)
Dieta , Cabras/fisiología , Yodo/administración & dosificación , Yodo/análisis , Lactancia/efectos de los fármacos , Leche/química , Animales , Suplementos Dietéticos , Grasas/análisis , Femenino , Lactancia/fisiología , Lactosa/análisis , Leche/efectos de los fármacos , Proteínas de la Leche/análisis , Yoduro de Potasio/administración & dosificación , Factores de TiempoRESUMEN
CONTEXT: Iodine deficiency disorders are a major public health problem, and programs have been implemented to improve iodine nutrition. OBJECTIVE: The objective of the study was to verify the effects of voluntary iodine prophylaxis in a small rural community (Pescopagano, Italy). DESIGN: The design of the study was the evaluation of the prevalence of thyroid disorders 15 years after a previous survey conducted before iodine prophylaxis. SETTING: The setting for this study was a general community survey. PARTICIPANTS: One thousand one hundred forty-eight residents were examined in 2010 and 1411 in 1995. RESULTS: In 2010, 757 of 1148 subjects (65.9%) routinely used iodized salt, urinary iodine excretion being significantly higher than in 1955 (median 98.0 µg/L, vs 55.0 µg/L, P < .0001). The prevalence of goiter was lower in 2010 than in 1995 (25.8% vs 46.1%, P < .0001), mainly due to the reduction of diffuse goiter (10.3% vs 34.0%, P < .0001). In 2010 vs 1995, thyroid autonomy in subjects younger than 45 years old (3 of 579, 0.5% vs 25 of 1010, 2.5% P = .004) and nonautoimmune hyperthyroidism in subjects older than 45 years old (8 of 569, 1.4% vs 18 of 401, 4.5%, P = .03) were less frequent. The prevalence of hypothyroidism was higher in 2010 vs 1995 (5.0% vs 2.8%, P = .005), mainly because of an increased frequency of subclinical hypothyroidism in subjects younger than 15 years old (7 of 83, 8.4% vs 0 of 419, 0.0%, P < .0001). Accordingly, serum thyroid autoantibodies (19.5% vs 12.6%; P < .0001) and Hashimoto's thyroiditis (14.5% vs 3.5%; P < .0001) were more frequent in 2010 than in 1995. CONCLUSIONS: In the present work, the role of voluntary iodine prophylaxis was assessed in a small rural community relatively segregated, in which genetic and other environmental factors have not substantially changed between the 2 surveys. Iodine intake strongly affected the pattern of thyroid diseases, but the benefits of correcting iodine deficiency (decreased prevalence of goiter and thyroid autonomy in younger subjects and reduced frequency of nonautoimmune hyperthyroidism in older subjects) far outweighs the risk of development of thyroid autoimmunity and mild hypothyroidism in youngsters.
Asunto(s)
Bocio/epidemiología , Yodo/deficiencia , Población Rural/estadística & datos numéricos , Cloruro de Sodio Dietético/uso terapéutico , Enfermedades de la Tiroides/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Femenino , Bocio/diagnóstico por imagen , Bocio/prevención & control , Enfermedad de Graves/diagnóstico por imagen , Enfermedad de Graves/epidemiología , Enfermedad de Hashimoto/diagnóstico por imagen , Enfermedad de Hashimoto/epidemiología , Encuestas Epidemiológicas , Humanos , Hipertiroidismo/diagnóstico por imagen , Hipertiroidismo/epidemiología , Lactante , Yodo/uso terapéutico , Yodo/orina , Italia/epidemiología , Masculino , Persona de Mediana Edad , Prevalencia , Enfermedades de la Tiroides/diagnóstico por imagen , Enfermedades de la Tiroides/prevención & control , Pruebas de Función de la Tiroides , Ultrasonografía , Adulto JovenRESUMEN
BACKGROUND: It has been observed that migraineurs show a higher risk of thrombosis and that the most frequent symptom reported by patients with antiphospholipid syndrome is headache, especially migraine. OBJECTIVES: The aim of our research was to evaluate the prevalence of antiphospholipid antibodies (aPL) in a random cohort of migraineurs. PATIENTS/METHODS: This analytic, comparative case study was performed to evaluate the prevalence of antiphospholipid antibodies by comparing a population of migraineurs with and without aura with sex- and age-matched controls. Both the diagnosis of migraine and the laboratory diagnosis of aPL positivity were made on the basis of the most recent international guidelines. RESULTS: Between September 2008 and August 2009, we recruited 284 consecutive patients (225 women and 59 men, 203 without aura and 81 with aura) and 225 controls (174 women and 51 men). Positivity for at least one test for aPL (LAC, ACA IgG or antiß2GLP1 IgG) was detected and confirmed in 12% (n = 33) of patients and in 3% (n = 7) of controls (odds ratio, 4.08; confidence interval, 1.77-9:39; P = 0.0004). Two of the patients had triple positivity for aPL (LAC, ACA and antiß2GLP1) and one had double positivity (LAC and antiß2GLP1); none of the controls showed multiple positivity. CONCLUSIONS: Our data show that migraineurs have a significantly higher prevalence of antiphospholipid antibodies, and point towards the fact that the two conditions may be comorbid or even that migraine may be an early sign for identifying patients with aPL positivity.